Especially in NB, where clinical trials of ALK inhibitors alone or in combination with standard chemotherapy agents are planned, it would be reasonable to assume that numerous instances of resistance will involve activation of AXL, and potentially the development of EMT. This evidence concerns the gene AXL and neuroblastoma.